Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Ascendis Pharma A (ASND) Invested Capital (2016 - 2025)

Ascendis Pharma A's Invested Capital history spans 8 years, with the latest figure at $281.2 million for Q4 2023.

  • For Q4 2023, Invested Capital fell 64.28% year-over-year to $281.2 million; the TTM value through Dec 2023 reached $281.2 million, down 64.28%, while the annual FY2023 figure was $282.8 million, 65.24% down from the prior year.
  • Invested Capital for Q4 2023 was $281.2 million at Ascendis Pharma A, down from $787.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.0 billion in Q4 2021 and bottomed at $281.2 million in Q4 2023.
  • The 5-year median for Invested Capital is $787.4 million (2022), against an average of $749.7 million.
  • The largest annual shift saw Invested Capital surged 106.77% in 2019 before it plummeted 64.28% in 2023.
  • A 5-year view of Invested Capital shows it stood at $660.9 million in 2019, then surged by 51.3% to $1000.0 million in 2020, then increased by 1.89% to $1.0 billion in 2021, then dropped by 22.72% to $787.4 million in 2022, then tumbled by 64.28% to $281.2 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Invested Capital are $281.2 million (Q4 2023), $787.4 million (Q4 2022), and $1.0 billion (Q4 2021).